Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGX-109 in healthy volunteers
NCT06799416Phase 1Completed
- Sponsor
- argenx
- Start
- Jan 2025
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing ARGX-109 with Placebo (2 arms). Primary endpoints: Adverse Events at 16 weeks, Serious Adverse Events at 16 weeks and 1 more. Started Jan 2025; status: completed.
02
Drugs
gerilimzumab
Beyond the preview
Go deeper on NCT06799416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06799416.